REFERENCES
1. Ji Y, Yang K, Peng S, et al. Kaposiform haemangioendothelioma:
clinical features, complications and risk factors for Kasabach-Merritt
phenomenon. Br J Dermatol 2018;179(2):457-463. DOI: 10.1111/bjd.16601.
2. Croteau SE, Liang MG, Kozakewich HP, et al. Kaposiform
hemangioendothelioma: atypical features and risks of Kasabach-Merritt
phenomenon in 107 referrals. J Pediatr 2013;162(1):142-7. DOI:
10.1016/j.jpeds.2012.06.044.
3. Gruman A, Liang MG, Mulliken JB, et al. Kaposiform
hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad
Dermatol 2005;52(4):616-22. DOI: 10.1016/j.jaad.2004.10.880.
4. Seo SK, Suh JC, Na GY, Kim IS, Sohn KR. Kasabach-Merritt syndrome:
identification of platelet trapping in a tufted angioma by
immunohistochemistry technique using monoclonal antibody to CD61.
Pediatr Dermatol 1999;16(5):392-4. DOI:
10.1046/j.1525-1470.1999.00103.x.
5. Douma RA, Oduber CE, Gerdes VE, et al. Chronic pulmonary embolism in
Klippel-Trenaunay syndrome. J Am Acad Dermatol 2012;66(1):71-7. DOI:
10.1016/j.jaad.2010.12.002.
6. Oduber CE, Young-Afat DA, van der Wal AC, van Steensel MA, Hennekam
RC, van der Horst CM. The persistent embryonic vein in Klippel-Trenaunay
syndrome. Vasc Med 2013;18(4):185-91. DOI: 10.1177/1358863X13498463.
7. Oduber CE, van Beers EJ, Bresser P, van der Horst CM, Meijers JC,
Gerdes VE. Venous thromboembolism and prothrombotic parameters in
Klippel-Trenaunay syndrome. Neth J Med 2013;71(5):246-52.
(https://www.ncbi.nlm.nih.gov/pubmed/23799311).
8. Keppler-Noreuil KM, Lozier JN, Sapp JC, Biesecker LG.
Characterization of thrombosis in patients with Proteus syndrome. Am J
Med Genet A 2017;173(9):2359-2365. DOI: 10.1002/ajmg.a.38311.
9. van Es J, Kappelhof NA, Douma RA, Meijers JCM, Gerdes VEA, van der
Horst C. Venous thrombosis and coagulation parameters in patients with
pure venous malformations. Neth J Med 2017;75(8):328-334.
(https://www.ncbi.nlm.nih.gov/pubmed/29219827).
10. Sepulveda P, Zavala A, Zuniga P. Factors associated with thrombotic
complications in pediatric patients with vascular malformations. J
Pediatr Surg 2017;52(3):400-404. DOI: 10.1016/j.jpedsurg.2016.10.048.
11. Reis J, 3rd, Alomari AI, Trenor CC, 3rd, et al. Pulmonary
thromboembolic events in patients with congenital lipomatous overgrowth,
vascular malformations, epidermal nevi, and spinal/skeletal
abnormalities and Klippel-Trenaunay syndrome. J Vasc Surg Venous Lymphat
Disord 2018;6(4):511-516. DOI: 10.1016/j.jvsv.2018.01.015.
12. Harvey JA, Nguyen H, Anderson KR, et al. Pain, psychiatric
comorbidities, and psychosocial stressors associated with
Klippel-Trenaunay syndrome. J Am Acad Dermatol 2018;79(5):899-903. DOI:
10.1016/j.jaad.2018.05.1245.
13. Hermans C, Dessomme B, Lambert C, Deneys V. [Venous malformations
and coagulopathy]. Ann Chir Plast Esthet 2006;51(4-5):388-93. DOI:
10.1016/j.anplas.2006.07.009.
14. Lee A, Driscoll D, Gloviczki P, Clay R, Shaughnessy W, Stans A.
Evaluation and management of pain in patients with Klippel-Trenaunay
syndrome: a review. Pediatrics 2005;115(3):744-9. DOI:
10.1542/peds.2004-0446.
15. Mack JM, Verkamp B, Richter GT, Nicholas R, Stewart K, Crary SE.
Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
Pediatr Blood Cancer 2019;66(10):e27896. DOI: 10.1002/pbc.27896.
16. Nakano TA, Zeinati C. Venous Thromboembolism in Pediatric Vascular
Anomalies. Front Pediatr 2017;5:158. DOI: 10.3389/fped.2017.00158.
17. Drolet BA, Trenor CC, 3rd, Brandao LR, et al. Consensus-derived
practice standards plan for complicated Kaposiform hemangioendothelioma.
J Pediatr 2013;163(1):285-91. DOI: 10.1016/j.jpeds.2013.03.080.
18. Croteau SE, Kozakewich HP, Perez-Atayde AR, et al. Kaposiform
lymphangiomatosis: a distinct aggressive lymphatic anomaly. J Pediatr
2014;164(2):383-8. DOI: 10.1016/j.jpeds.2013.10.013.
19. Ji Y, Chen S, Peng S, Xia C, Li L. Kaposiform lymphangiomatosis and
kaposiform hemangioendothelioma: similarities and differences. Orphanet
J Rare Dis 2019;14(1):165. DOI: 10.1186/s13023-019-1147-9.
20. Fernandes VM, Fargo JH, Saini S, et al. Kaposiform
lymphangiomatosis: unifying features of a heterogeneous disorder.
Pediatr Blood Cancer 2015;62(5):901-4. DOI: 10.1002/pbc.25278.
21. Barclay SF, Inman KW, Luks VL, et al. A somatic activating NRAS
variant associated with kaposiform lymphangiomatosis. Genet Med
2019;21(7):1517-1524. DOI: 10.1038/s41436-018-0390-0.
22. Le Cras TD, Mobberley-Schuman PS, Broering M, Fei L, Trenor CC, 3rd,
Adams DM. Angiopoietins as serum biomarkers for lymphatic anomalies.
Angiogenesis 2017;20(1):163-173. DOI: 10.1007/s10456-016-9537-2.
23. North PE, Kahn T, Cordisco MR, Dadras SS, Detmar M, Frieden IJ.
Multifocal lymphangioendotheliomatosis with thrombocytopenia: a newly
recognized clinicopathological entity. Arch Dermatol
2004;140(5):599-606. DOI: 10.1001/archderm.140.5.599.
24. Droitcourt C, Boccara O, Fraitag S, Favrais G, Dupuy A, Maruani A.
Multifocal Lymphangioendotheliomatosis With Thrombocytopenia: Clinical
Features and Response to Sirolimus. Pediatrics 2015;136(2):e517-22. DOI:
10.1542/peds.2014-2410.
25. Baselga E, Cordisco MR, Garzon M, Lee MT, Alomar A, Blei F. Rapidly
involuting congenital haemangioma associated with transient
thrombocytopenia and coagulopathy: a case series. Br J Dermatol
2008;158(6):1363-70. DOI: 10.1111/j.1365-2133.2008.08546.x.
26. Dompmartin A, Acher A, Thibon P, et al. Association of localized
intravascular coagulopathy with venous malformations. Arch Dermatol
2008;144(7):873-7. DOI: 10.1001/archderm.144.7.873.
27. Hung JW, Leung MW, Liu CS, et al. Venous Malformation and Localized
Intravascular Coagulopathy in Children. Eur J Pediatr Surg
2017;27(2):181-184. DOI: 10.1055/s-0036-1582241.
28. Wang P, Zhou W, Tao L, Zhao N, Chen XW. Clinical analysis of
Kasabach-Merritt syndrome in 17 neonates. BMC Pediatr 2014;14:146. DOI:
10.1186/1471-2431-14-146.
29. Liu X, Li J, Qu X, et al. Clinical Outcomes for Systemic
Corticosteroids Versus Vincristine in Treating Kaposiform
Hemangioendothelioma and Tufted Angioma. Medicine (Baltimore)
2016;95(20):e3431. DOI: 10.1097/MD.0000000000003431.
30. Adams DM, Trenor CC, 3rd, Hammill AM, et al. Efficacy and Safety of
Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics
2016;137(2):e20153257. DOI: 10.1542/peds.2015-3257.
31. Tlougan BE, Lee MT, Drolet BA, Frieden IJ, Adams DM, Garzon MC.
Medical management of tumors associated with Kasabach-Merritt
phenomenon: an expert survey. J Pediatr Hematol Oncol 2013;35(8):618-22.
DOI: 10.1097/MPH.0b013e318298ae9e.
32. Burleigh A, Kanigsberg N, Lam JM. Topical rapamycin (sirolimus) for
the treatment of uncomplicated tufted angiomas in two children and
review of the literature. Pediatr Dermatol 2018;35(5):e286-e290. DOI:
10.1111/pde.13596.
33. Zhang X, Yang K, Chen S, Ji Y. Tacrolimus ointment for the treatment
of superficial kaposiform hemangioendothelioma and tufted angioma. J
Dermatol 2019;46(10):898-901. DOI: 10.1111/1346-8138.15031.
34. Fernandez-Pineda I, Lopez-Gutierrez JC, Ramirez G, Marquez C.
Vincristine-ticlopidine-aspirin: an effective therapy in children with
Kasabach-Merritt phenomenon associated with vascular tumors. Pediatr
Hematol Oncol 2010;27(8):641-5. DOI: 10.3109/08880018.2010.508299.
35. Fernandez-Pineda I, Lopez-Gutierrez JC, Chocarro G, Bernabeu-Wittel
J, Ramirez-Villar GL. Long-term outcome of
vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors
associated with Kasabach-Merritt phenomenon. Pediatr Blood Cancer
2013;60(9):1478-81. DOI: 10.1002/pbc.24543.
36. Moimeaux V, Taieb A, Legrain V, et al. Aspirin-ticlopidin in
Kasabach-Merritt syndrome. Lancet 1992;340(8810):55. DOI:
10.1016/0140-6736(92)92470-z.
37. Lopez V, Marti N, Pereda C, et al. Successful management of
Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon using
vincristine and ticlopidine. Pediatr Dermatol 2009;26(3):365-6. DOI:
10.1111/j.1525-1470.2009.00923.x.
38. Hanna SA, Prasad A, Lee J, Achan P. Topical Versus Intravenous
Administration of Tranexamic Acid in Primary Total Hip Arthroplasty: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Orthop Rev (Pavia) 2016;8(3):6792. DOI: 10.4081/or.2016.6792.
39. O’Rafferty C, O’Regan GM, Irvine AD, Smith OP. Recent advances in
the pathobiology and management of Kasabach-Merritt phenomenon. Br J
Haematol 2015;171(1):38-51. DOI: 10.1111/bjh.13557.
40. Phillips WG, Marsden JR. Kasabach-Merritt syndrome exacerbated by
platelet transfusion. J R Soc Med 1993;86(4):231-2.
(https://www.ncbi.nlm.nih.gov/pubmed/8505736).
41. Nguyen JT, Koerper MA, Hess CP, et al. Aspirin therapy in venous
malformation: a retrospective cohort study of benefits, side effects,
and patient experiences. Pediatr Dermatol 2014;31(5):556-60. DOI:
10.1111/pde.12373.
42. Mack JM, Richter GT, Crary SE. Effectiveness and Safety of Treatment
with Direct Oral Anticoagulant Rivaroxaban in Patients with Slow-Flow
Vascular Malformations: A Case Series. Lymphat Res Biol
2018;16(3):278-281. DOI: 10.1089/lrb.2017.0029.
43. Randrianarisoa E, Kopp HG, Balletshofer BM, et al. Management of
disseminated intravascular coagulopathy with direct factor Xa inhibitor
rivaroxaban in Klippel-Trenaunay syndrome. Blood Coagul Fibrinolysis
2013;24(7):766-70. DOI: 10.1097/MBC.0b013e3283626238.
44. Vandenbriele C, Vanassche T, Peetermans M, Verhamme P, Peerlinck K.
Rivaroxaban for the treatment of consumptive coagulopathy associated
with a vascular malformation. J Thromb Thrombolysis 2014;38(1):121-3.
DOI: 10.1007/s11239-013-1024-7.
45. Langbroek GB, Horbach SE, van der Vleuten CJ, Ubbink DT, van der
Horst CM. Compression therapy for congenital low-flow vascular
malformations of the extremities: A systematic review. Phlebology
2018;33(1):5-13. DOI: 10.1177/0268355516684694.
46. Dasgupta R, Patel M. Venous malformations. Semin Pediatr Surg
2014;23(4):198-202. DOI: 10.1053/j.sempedsurg.2014.06.019.
47. Zhuo KY, Russell S, Wargon O, Adams S. Localised intravascular
coagulation complicating venous malformations in children: Associations
and therapeutic options. J Paediatr Child Health 2017;53(8):737-741.
DOI: 10.1111/jpc.13461.
48. Mack JM, Pierce CD, Richter GT, et al. Analyzing coagulation
dynamics during treatment of vascular malformations with
thromboelastography. Pediatr Blood Cancer 2021;68(2):e28824. DOI:
10.1002/pbc.28824.
49. Ricci KW, Chute C, Hammill AM, Dasgupta R, Patel M. Retrospective
study of hematologic complications in patients with slow-flow vascular
malformations undergoing sclerotherapy. Pediatr Blood Cancer
2020:e28277. DOI: 10.1002/pbc.28277.
50. Binet Q, Lambert C, Hermans C. Dabigatran etexilate in the treatment
of localized intravascular coagulopathy associated with venous
malformations. Thromb Res 2018;168:114-120. DOI:
10.1016/j.thromres.2018.06.013.
51. Ardillon L, Lambert C, Eeckhoudt S, Boon LM, Hermans C. Dabigatran
etexilate versus low-molecular weight heparin to control consumptive
coagulopathy secondary to diffuse venous vascular malformations. Blood
Coagul Fibrinolysis 2016;27(2):216-9. DOI: 10.1097/MBC.0000000000000412.
52. Yasumoto A, Ishiura R, Narushima M, Yatomi Y. Successful treatment
with dabigatran for consumptive coagulopathy associated with extensive
vascular malformations. Blood Coagul Fibrinolysis 2017;28(8):670-674.
DOI: 10.1097/MBC.0000000000000666.